Ceria Therapeutics
Ceria Therapeutics is a privately held biotechnology company focused on developing novel RNA-based drug products for the treatment of acute and chronic inflammatory diseases. The company aims to address high unmet medical needs by targeting the root causes of dysregulated inflammation, thereby restoring natural healing processes and improving patient outcomes. Its core technology leverages nanoparticle delivery of microRNA therapeutics to modulate inflammatory pathways. Ceria operates research and development facilities in Tucson, Arizona and Aurora, Colorado, and collaborates with leading academic and clinical partners to advance preclinical and clinical programs for conditions such as acute lung injury, diabetic foot ulcers, and inflammatory bowel disease.
Ceria Therapeutics
What We Do
Therapeutic candidate leveraging RNA technology and nanoparticle delivery to block pulmonary inflammation and edema in acute lung injury and related conditions.
Drug candidate using nanoparticle-mediated delivery of microRNA molecules to treat non-healing diabetic foot ulcers by modulating inflammation and promoting tissue repair.
Drug candidate intended to treat diseases such as ulcerative colitis and Crohn’s disease by inhibiting inflammatory pathways via RNA therapeutics.
Therapeutic candidate leveraging RNA technology and nanoparticle delivery to block pulmonary inflammation and edema in acute lung injury and related conditions.
Drug candidate using nanoparticle-mediated delivery of microRNA molecules to treat non-healing diabetic foot ulcers by modulating inflammation and promoting tissue repair.
Drug candidate intended to treat diseases such as ulcerative colitis and Crohn’s disease by inhibiting inflammatory pathways via RNA therapeutics.
Application Area
Battlefield Resuscitation
Regenerative Medicine
Key People
Chief Executive Officer
Founder, Board of Directors
Independent Director
Chief Scientific Officer
Chief Medical Officer
Head of Operations
Chief Executive Officer
Founder, Board of Directors
Independent Director
Chief Scientific Officer
Chief Medical Officer
Head of Operations
News & Updates
Awarded a $2 million SBIR grant to advance the development of an RNA-based treatment for non-healing diabetic foot ulcers.
Received a $3.8 million contract from the U.S. Department of Defense to develop an acute lung injury therapeutic and field-use delivery system.
Awarded a $2.1 million SBIR grant for preclinical development of a treatment for acute lung injuries and related disorders.
Received a $300,000 SBIR grant for advancing a product candidate targeting non-healing diabetic foot ulcers.
Received a $250,000 grant from Colorado Advanced Industries program to accelerate development of products for inflammatory diseases.
Publication in scientific literature regarding nanoparticle-mediated delivery for wound healing.
Awarded a $2 million SBIR grant to advance the development of an RNA-based treatment for non-healing diabetic foot ulcers.
Received a $3.8 million contract from the U.S. Department of Defense to develop an acute lung injury therapeutic and field-use delivery system.
Awarded a $2.1 million SBIR grant for preclinical development of a treatment for acute lung injuries and related disorders.
Received a $300,000 SBIR grant for advancing a product candidate targeting non-healing diabetic foot ulcers.
Received a $250,000 grant from Colorado Advanced Industries program to accelerate development of products for inflammatory diseases.
Publication in scientific literature regarding nanoparticle-mediated delivery for wound healing.